<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02031939</url>
  </required_header>
  <id_info>
    <org_study_id>2013013</org_study_id>
    <secondary_id>SYSU5010Fund</secondary_id>
    <nct_id>NCT02031939</nct_id>
  </id_info>
  <brief_title>Randomized Controlled Study on Optimize Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer</brief_title>
  <official_title>Randomized Controlled Study on Optimize Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although neoadjuvant chemoradiotherapy has significantly reduced the risk of local recurrence&#xD;
      in locally advanced rectal cancer, systemic failure remains a predominant issue probably due&#xD;
      to the insufficient control of systemic micro-metastasis in the neoadjuvant treatment.&#xD;
      Induction chemotherapy is one of the most studied strategies. However, the efficacy of&#xD;
      induction chemotherapy prior to neoadjuvant chemotherapy remains controversial. In our&#xD;
      previous study, induction chemotherapy, gap chemotherapy combined with neoadjuvant&#xD;
      chemoradiotherapy can improve response rate of rectal cancer patients, but the results have&#xD;
      not been confirmed in clinical trial. Whether this new kind of treatment can optimize&#xD;
      neoadjuvant therapy for locally advanced rectal cancer or not is still a big problem in&#xD;
      clinical practice. This study will focus on how to optimize neoadjuvant chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 2014</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Actual">December 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>disease free survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respond rate</measure>
    <time_frame>One week after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">556</enrollment>
  <condition>Advanced Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Standard chemoradiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard chemoradiotherapy (Capecitabine 825mg/m2 combined with radiotherapy )</description>
  </arm_group>
  <arm_group>
    <arm_group_label>induction and gap chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>induction chemotherapy (Capecitabine 2000mg/m2 +oxaliplatine 130mg/m2) + standard chemoradiotherapy (Capecitabine 2000mg/m2 combined with radiotherapy) + gap chemotherapy (Capecitabine 2000mg/m2 + oxaliplatine 130mg/m2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Induction and gap chemotherapy (Capecitabine combine with oxaliplatin)</intervention_name>
    <description>All rectal cancer patients in this group will receive induction, gap chemotherapy(capecitabine combine with oxaliplatin) alone with standard chemoradiotherapy before surgery.</description>
    <arm_group_label>induction and gap chemotherapy</arm_group_label>
    <other_name>Xeloda</other_name>
    <other_name>Eloxatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>standard chemoradiotherapy</intervention_name>
    <description>All rectal patients in this group will receive standard chemoradiotherapy and surgical resection.</description>
    <arm_group_label>Standard chemoradiotherapy</arm_group_label>
    <arm_group_label>induction and gap chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathological confirmed rectal cancer&#xD;
&#xD;
          -  Clinical stage T3-4 or T any N1&#xD;
&#xD;
          -  No metastasis&#xD;
&#xD;
          -  Distance of tumor is no more than 10cm from anal verge&#xD;
&#xD;
          -  No previous radiotherapy&#xD;
&#xD;
          -  Age ranged from 18 to 70&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group score system 0-1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinical stage T1-2 N0&#xD;
&#xD;
          -  Distance metastasis&#xD;
&#xD;
          -  Multiple primary tumor&#xD;
&#xD;
          -  Cachexy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhen-Hai Lu, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sun Yat-Sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 30, 2013</study_first_submitted>
  <study_first_submitted_qc>January 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2014</study_first_posted>
  <last_update_submitted>March 21, 2021</last_update_submitted>
  <last_update_submitted_qc>March 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Zhen-Hai Lu</investigator_full_name>
    <investigator_title>Pofessor</investigator_title>
  </responsible_party>
  <keyword>Rectal cancer</keyword>
  <keyword>neoadjuvant chemoradiotherapy</keyword>
  <keyword>optimization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

